NASDAQ:ADMP

Adamis Pharmaceuticals - ADMP Stock Forecast, Price & News

$0.22

+0.01 (+4.76%)

(As of 02/8/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.21
▼
$0.23
50-Day Range: $0.14
▼
$0.23
52-Week Range: $0.12
▼
$0.73

Volume: 359,124 shs
Average Volume: 452,698 shs
Market Capitalization: $33.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Adamis Pharmaceuticals (NASDAQ:ADMP) Stock

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMP Stock News Headlines

February 7, 2023 | americanbankingnews.com

Adamis Pharmaceuticals (NASDAQ:ADMP) Now Covered by Analysts at StockNews.com

January 31, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Adamis Pharmaceuticals (NASDAQ:ADMP)

February 9, 2023 | Investing Trends (Ad)

YIKES! 220 Pounds of Graphite in Each EV Battery?

Most don't know that today's EV batteries contain more graphite than any other essential ingredient... more than lithium, copper or aluminum! The megatrend of electrifying vehicles only adds to graphite demand, expected to skyrocket 1,050% by 2030. Investors have been frustrated in their search for a Made In America solution – until now.

January 30, 2023 | americanbankingnews.com

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) Short Interest Update

December 29, 2022 | finance.yahoo.com

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q3 2022 Earnings Call Transcript

November 15, 2022 | finanznachrichten.de

Adamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 15, 2022 | seekingalpha.com

Adamis Pharmaceuticals Corporation (ADMP) Q3 2022 Earnings Call Transcript

November 15, 2022 | finance.yahoo.com

Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

February 9, 2023 | Investing Trends (Ad)

The Lithium "Lie"

Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China controls more than 90% of this vital ingredient. But the U.S. just classified graphite as "essential for America's National Defense"... and one little-known company is looking to win big in the energy war with China.

November 12, 2022 | msn.com

A Preview Of Adamis Pharmaceuticals's Earnings

November 7, 2022 | finance.yahoo.com

Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update

October 18, 2022 | msn.com

Why fuboTV Shares Are Trading Higher By 11%; Here Are 22 Stocks Moving Premarket

October 12, 2022 | msn.com

Why Cango Shares Are Trading Higher; Here Are 27 Stocks Moving Premarket

October 5, 2022 | marketwatch.com

Adamis Pharmaceuticals Shares Jump 14% On Potential Sale, Strategic Alternatives

October 3, 2022 | nasdaq.com

Adamis Pharma To Explore Strategic Alternatives; Stock Up 10%

October 3, 2022 | finance.yahoo.com

Adamis Announces Review of Strategic Alternatives

September 30, 2022 | seekingalpha.com

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

September 23, 2022 | seekingalpha.com

ADMP Adamis Pharmaceuticals Corporation

September 21, 2022 | seekingalpha.com

Adamis says Phase 2/3 trial for COVID-19 therapy did not reach main goal

September 21, 2022 | marketwatch.com

Adamis Pharmaceuticals Sink to New Lows After Study Failure >ADMP

September 21, 2022 | finance.yahoo.com

Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy

September 21, 2022 | marketwatch.com

Adamis Ends Tempol Covid-19 Study After Main Endpoint Missed >ADMP

September 21, 2022 | finance.yahoo.com

Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

September 12, 2022 | finance.yahoo.com

Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

August 30, 2022 | thestreet.com

Adamis Pharmaceuticals Corporation

August 12, 2022 | finance.yahoo.com

Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders

August 11, 2022 | seekingalpha.com

Adamis Pharmaceuticals Corporation (ADMP) CEO David J. Marguglio on Q2 2022 Results - Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMP Company Calendar

Last Earnings: 11/14/2022
Today: 2/09/2023
Next Earnings (Estimated): 3/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ADMP
CUSIP: N/A
CIK: 887247
Web: www.adamispharmaceuticals.com
Phone: (858) 997-2400
Fax: N/A
Employees: 116
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,830,000.00
Net Margins: N/A
Pretax Margin: -2,069.43%
Return on Equity: -237.90%
Return on Assets: -124.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.14
Quick Ratio: 1.01

Sales & Book Value

Annual Sales: $2.21 million
Price / Sales: 14.93
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.17 per share
Price / Book: 1.29

Miscellaneous

Outstanding Shares: 149,980,000
Free Float: 148,033,000
Market Cap: $33.00 million
Optionable: Optionable
Beta: 1.32

Key Executives

David J. Marguglio
President, Chief Executive Officer & Director

David C. Benedicto
Chief Financial & Accounting Officer

Thomas H. Moll
Vice President-Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ADMP Stock - Frequently Asked Questions

How have ADMP shares performed in 2023?: Adamis Pharmaceuticals' stock was trading at $0.1693 at the beginning of 2023. Since then, ADMP stock has increased by 29.9% and is now trading at $0.22.
View the best growth stocks for 2023 here.
Are investors shorting Adamis Pharmaceuticals?: Adamis Pharmaceuticals saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 1,910,000 shares, a decrease of 23.9% from the December 31st total of 2,510,000 shares. Based on an average daily trading volume, of 754,700 shares, the short-interest ratio is presently 2.5 days.
View Adamis Pharmaceuticals' Short Interest.
When is Adamis Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our ADMP earnings forecast.
How were Adamis Pharmaceuticals' earnings last quarter?: Adamis Pharmaceuticals Co. (NASDAQ:ADMP) posted its earnings results on Monday, November, 14th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $1.51 million during the quarter.
What other stocks do shareholders of Adamis Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

What is Adamis Pharmaceuticals' stock symbol?: Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."
Who are Adamis Pharmaceuticals' major shareholders?: Adamis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David C Benedicto, David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins and Ronald B Moss.
View institutional ownership trends.
How do I buy shares of Adamis Pharmaceuticals?: Shares of ADMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Adamis Pharmaceuticals' stock price today?: One share of ADMP stock can currently be purchased for approximately $0.22.
How much money does Adamis Pharmaceuticals make?: Adamis Pharmaceuticals (NASDAQ:ADMP) has a market capitalization of $33.00 million and generates $2.21 million in revenue each year.
How many employees does Adamis Pharmaceuticals have?: The company employs 116 workers across the globe.
How can I contact Adamis Pharmaceuticals?: Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.adamispharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (858) 997-2400 or via email at mflather@adamispharma.com.

This page (NASDAQ:ADMP) was last updated on 2/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial